Does neoadjuvant chemoradiation downstage esophageal carcinoma?

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Neoadjuvant chemoradiotherapy is a standard treatment for esophageal carcinoma, aiming to reduce tumor size and enhance survival.
• Endoscopic ultrasound (EUS) is the leading diagnostic tool for staging esophageal cancer, assessing tumor (T) and lymph node (N) status.
• Limited data exist on the correlation between EUS staging and post-resection histological staging in patients undergoing neoadjuvant therapy for esophageal cancer.

Purpose of the Study:

• To evaluate the impact of neoadjuvant chemoradiotherapy on T and N staging as determined by EUS.
• To compare the accuracy of EUS staging before and after neoadjuvant therapy.
• To assess the effect of neoadjuvant therapy on patient survival and operative outcomes.

Main Methods:

• A retrospective analysis compared two groups of esophageal cancer patients staged by EUS.
• One group (33 patients) received neoadjuvant chemoradiotherapy (Walsh protocol) followed by resection.
• A control group (22 patients) underwent resection without neoadjuvant therapy; histological staging and survival were compared.

Main Results:

• EUS demonstrated high accuracy in predicting final histological stage.
• Neoadjuvant chemoradiotherapy resulted in downstaging of T and N status in 36% of patients, compared to 5% in the control group.
• Patients receiving neoadjuvant therapy showed significantly prolonged survival (20.6 months vs. 9.6 months) and a higher rate of complete response (15%).

Conclusions:

• EUS is a reliable method for staging esophageal carcinoma.
• Neoadjuvant chemoradiotherapy effectively downstages esophageal cancer, leading to a significant survival benefit.
• While neoadjuvant therapy improves survival, it may be associated with increased operative risks.